🔎 Trials Near Me

Beranda › Sirosis › New York

Uji klinis Sirosis di New York

6 studi untuk Sirosis mencari peserta di lokasi di New York.

Kota di New York

Teks studi resmi (Bahasa Inggris)

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  • NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn
  • Basil Clinical, Laurelton
  • Icahn School of Medicine at Mount Sinai, New York
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06632444

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

  • Columbia University Medical Center, New York
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07325526

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

  • New York Presbyterian/Weill Cornell, New York
  • Columbia University Iriving School of Medicine, New York
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05832229

National Liver Cancer Screening Trial

  • The Feinstein Institutes, Northwell Health, Inc., Manhasset
Menerima pesertaFase 4
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06084234

A Study of SIPLIZUMAB in AILD and LT Patients

  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Nov 2025 · NCT06455280

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

  • Weill Cornell Medicine, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Montefiore Medical Center, New York
Menerima pesertaStudi observasional
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 20 Okt 2025 · NCT04613921

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.